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ORIGINAL ARTICLE
Italian survey on non-steroidal anti-inflammatory drugs 
and gastrointestinal bleeding in children
Observational Study
Sabrina Cardile, Massimo Martinelli, Arrigo Barabino, Paolo Gandullia, Salvatore Oliva, Giovanni Di Nardo, 
Luigi Dall'Oglio, Francesca Rea, Gian Luigi de' Angelis, Barbara Bizzarri, Graziella Guariso, Enzo Masci, 
Annamaria Staiano, Erasmo Miele, Claudio Romano
Abstract
AIM: To investigate gastrointestinal complications 
associated with non-steroidal anti-inflammatory drug 
(NSAIDs) use in children. 
METHODS: A retrospective, multicenter study 
was conducted between January 2005 and January 
2013, with the participation of 8 Italian pediatric 
gastroenterology centers. We collected all the 
cases of patients who refer to emergency room for 
suspected gastrointestinal bleeding following NSAIDs 
consumption, and underwent endoscopic evaluation. 
Previous medical history, associated risk factors, 
symptoms and signs at presentation, diagnostic 
procedures, severity of bleeding and management of 
gastrointestinal bleeding were collected. In addition, 
data regarding type of drug used, indication, dose, 
duration of treatment and prescriber (physician or self-
medication) were examined. 
RESULTS: Fifty-one patients, including 34 males, were 
enrolled (median age: 7.8 years). Ibuprofen was the 
most used NSAID [35/51 patients (68.6%)]. Pain was 
the most frequent indication for NSAIDs use [29/51 
patients (56.9%)]. Seven patients had positive family 
history of Helicobacter pylori  (H. pylori ) infection or 
peptic ulcer, and 12 had associated comorbidities. 
Twenty-four (47%) out of 51 patients used medication 
inappropriately. Hematemesis was the most frequent 
symptom (33.3%). Upper gastrointestinal endoscopy 
revealed gastric lesions in 32/51 (62%) patients, 
duodenal lesions in 17 (33%) and esophageal lesions in 
8 (15%). In 10/51 (19.6%) patients, a diagnosis of H. 
pylori  gastritis was made. Forty-eight (94%) patients 
underwent medical therapy, with spontaneous bleeding 
resolution, while in 3/51 (6%) patients, an endoscopic 
hemostasis was needed.
CONCLUSION: The data collected in this study 
confirms that adverse events with the involvement of 
the gastrointestinal tract secondary to NSAID use are 
also common in children 
Key words: Hematemesis; Gastrointestinal bleeding; 
Non-steroidal anti-inflammatory drug; Melena; Pediatrics
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Core tip:  It is known that non-steroidal anti-
inflammatory drug (NSAIDs) are one of the most 
extensively used medications. Adverse effects 
associated with their use are commonly reported in the 
gastrointestinal tract. Data on children are limited and 
evidence is based mainly on case reports, and relatively 
small cohort studies. Our manuscript represents 
the first Italian survey focusing on gastrointestinal 
bleeding occurrences following NSAIDs consumption 
in a pediatric population. A high number of self-
prescriptions and inappropriate use represent the most 
alarming data. Our data show that the risk of adverse 
events seems to be related to improper use rather than 
to NSAIDs safety profile.
Cardile S, Martinelli M, Barabino A, Gandullia P, Oliva S, 
Di Nardo G, Dall’Oglio L, Rea F, de’ Angelis GL, Bizzarri 
B, Guariso G, Masci E, Staiano A, Miele E, Romano C. 
Italian survey on non-steroidal anti-inflammatory drugs and 
gastrointestinal bleeding in children. World J Gastroenterol 
2016; 22(5): 1877-1883  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v22/i5/1877.htm  DOI: http://dx.doi.
org/10.3748/wjg.v22.i5.1877
INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) 
are perhaps some of the most extensively used 
medications in the world for their anti-inflammatory 
and antipyretic effects, in both adults and children[1,2]. 
They are frequently used for fever control and 
are generally considered to be safe. Despite their 
benefits, there is evidence for gastrointestinal (GI) 
complications, including peptic ulcer disease, bleeding 
and perforation. These GI events result in more 
than 100000 hospitalizations annually in the United 
States and in 7000-10000 deaths, especially among 
those who belong to high-risk categories[3-5]. The 
pathogenesis of NSAID gastrointestinal toxicity is 
topical injury to the mucosa, and systemic effects 
associated with mucosal prostaglandin depletion 
derived from COX-1[6]. Adverse effects associated 
with the use of NSAIDs are most commonly reported 
in the upper GI tract; and in addition to damage to 
the gastric mucosa, NSAIDs may also cause mucosal 
damage in the small intestine and colon[7]. The clinical 
presentation of GI complications from NSAIDs is not 
always typical, since many patients may have non-
specific symptoms and signs, such as dyspepsia, 
nausea, vomiting, abdominal pain, diarrhea and 
anemia. Only acute GI bleeding (hematemesis and/or 
melena) is considered the typical clinical manifestation 
of peptic damage from NSAIDs[5]. Data on children are, 
however, limited, and the evidence is based mainly on 
case reports, series and relatively small cohorts[8-13]. 
NSAIDs were associated with 12 out of 390 fatal 
events (0.03%) in a British study conducted from 1990 
to 2000[11]. In another survey, among children affected 
by rheumatoid arthritis on long-term treatment with 
NSAIDs, more than 75% of patients had abdominal 
pain, gastritis, antral erosions or ulcers[12]. More 
recently, Grimaldi-Bensouda et al[13] reported that 83 
out of 177 (46.9%) children with upper gastrointestinal 
bleeding (UGIB) had taken NSAIDs at least once 
before the index date, with an adjusted odds ratio 
(OR) of 8.2. GI complications related to the use of 
NSAIDs is therefore well known and well studied in the 
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adult population, but studies are needed in pediatrics 
in order to define preventive strategies. The primary 
aim of our survey was to retrospectively collect all the 
cases of GI bleeding following NSAIDs consumption in 
the Italian pediatric population; as a secondary aim, 
we also evaluated appropriateness of the prescription, 
clinical presentation, and correlated risk factors.
MATERIALS AND METHODS
A retrospective, multicenter study was conducted, 
with the participation of eight Italian pediatric 
gastroenterology centers. All the centers involved were 
asked to retrospectively collect data from pediatric 
patients who had presented at the emergency room 
for suspected gastrointestinal bleeding, following 
NSAIDs consumption. The cases were collected from 
January 2005 to January 2013. Previous medical 
history, symptoms and signs at presentation, 
diagnostic procedures, severity of bleeding and 
treatment to manage GI bleeding were collected. 
Endoscopic procedure was considered an emergency 
treatment if carried out within 12 h from GI bleeding, 
while all the procedures performed after 12 h were 
considered elective treatments. Physicians were 
required to report endoscopy findings, if performed. 
Esophageal damage was described according to the 
Los Angeles Classification[14]. Forrest classification 
was used to describe ulcerations[15]. Risk factors, 
including portal hypertension, history of GI bleeding 
or peptic disease, gastro-oesophageal reflux disease 
(GERD), Helicobacter pylori (H. pylori) infection and 
coagulation disorders were also recorded. In addition, 
data regarding type of drug used, indication, dose, 
duration of treatment and prescriber (physician or 
self-medication) were collected. The appropriateness 
of drug use was also evaluated. It was considered 
inappropriate if the weight-dose, number of admini-
strations per day or age of the patient were not in 
accordance with the Package Inserts of the drug. 
Informed consent was obtained from the parents of 
participating children. The study was approved by 
the Scientific Committee of the Coordinating Unit 
(University of Messina, Prot. E 37/12, 07/09/2012). 
Statistical analysis
Variables were screened for distribution, and ap-
propriate parametric or non-parametric tests were 
adopted as necessary. The Student’s t test, the Mann-
Whitney test for continuous variables, and the χ 2 and 
Fisher’s exact tests for categorical variables were 
used where appropriate. In order to distinguish age-
based differences, enrolled children were divided into 
three subgroups: age ≤ 3 years; age > 3 years ≤ 
7 years; age > 7 years. Statistical significance was 
predetermined as p < 0.05. Percentages were rounded 
to the nearest whole numbers. SPSS version 20 was 
used for all statistical analyses.
RESULTS 
Fifty-one patients, including 34 males, were enrolled 
in the study (median age: 7.8 years; range 5 mo to 
18 years) between January 2005 and January 2013. 
Baseline characteristics of the enrolled patients are 
shown in Table 1. There was a progressive increase 
of cases between 2005 and 2013, with the highest 
number of cases reported in 2011 [18/51 (35.2%)]. 
Drug use and indications
Ibuprofen was the most used NSAID [35/51 (68.6%)], 
followed by ketoprofen [5/51 (9.8%)] and acetylsa-
licylic acid [4/51(7.8%)]. Other NSAIDs used included 
flurbiprofen, ketoralac, naproxen, niflumic acid and 
nimesulide. All NSAIDs associated with GI bleeding 
are shown in Table 2. Patients’ age was significantly 
lower in those using ibuprofen compared with patients 
taking other NSAIDs [median age 5.5 years, range 5 
mo-15 years vs median age 11 years, range 2.2-15 
years; p = 0.004)]. Pain was the most frequent 
indication for NSAIDs use, being reported in 29 
of 51 patients (56.9%), followed by fever [21/51 
patients (41%)], and inflammation [(1/51 (2%)] 
(Table 1). The median duration of NSAID use prior to 
bleeding was 4 d (range 1-263 d). An analysis of the 
appropriateness of drug use showed that 24 (47%) of 
51 patients used medications inappropriately in terms 
of weight-appropriate dose [8/24 (33.3%)], number of 
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Table 1  Baseline characteristics of 51 patients with gastro­
intestinal bleeding following non­steroidal anti­inflammatory 
drug consumption  n  (%)
Characteristics Patients 
Median age (range) 7.6 yr 
(5 mo-15.3 yr)
Gender
   Male 34 (66.7)
   Female 17 (33.3)
Indications for drug use
   Pain 29 (56.9)
   Fever 21 (41.2)
   Inflammation 1 (2)
Comorbidities (n = 12)
   Cardiovascular disease 1 (2)
   Celiac disease 1 (2)
   Cystic fibrosis 1 (2)
   Diaphragmatic hernia 1 (2)
   GERD 1 (2)
   H. pylori infection    3 (5.9)
   IBD 1 (2)
   Neurological diseases/cognitive impairment    2 (3.9)
   Pulmonary atelectasis 1 (2)
Other medications (n = 19)
   Corticosteroids   7 (13.7)
   Antibiotics 10 (19.6)
   Acetaminophen 1 (2)
   Baclofen 1 (2)
H. pylori: Helicobacter pylori; GERD: Gastroesophageal reflux disease; IBD: 
Inflammatory bowel disease; NSAIDs: Non-steroidal anti-inflammatory 
drugs.
Cardile S et al . NSAIDs and gastrointestinal bleeding in children
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GI endoscopic lesions varied in different age groups. 
Younger children (age ≤ 3 years) showed more 
proximal lesions (esophageal and gastric) compared 
with older age groups (100% vs 82.7% vs 62.5%, p = 
0.04). Duodenal lesions were significantly more in the 
oldest group (> 7 years) (37.5% vs 18.5% vs 0%, p 
= 0.04). Colonic lesions were documented in 2 of 51 
patients. Detailed endoscopic findings are shown in 
Table 4.
Additional risk factors for GI bleeding
Twelve (23.5%) of 51 patients had associated 
comorbidities (Table 1). A family history of peptic 
disease was identified in 5/51 (9.8%) patients. In 3 
(5.8%) of 51 patients, a family history of H. pylori 
was recorded, while in 10 (19.6%) of 51 patients, 
a histologic diagnosis of H. pylori active gastritis 
was made. Nineteen (37.3%) patients had taken 
other drugs contemporarily, including steroids [7/19 
(36.8%)], antibiotics [10/19 (52.6%)], acetaminophen 
[1/19 (5.3%)], and baclofen [1/19 (5.3%)]. Five 
(9.8%) patients were taking gastro-protective drugs, 
including proton pump inhibitors (PPI) (4 patients) 
and H2 receptor antagonists (H2RAs) (1 patient). The 
duration of therapy [median 6 d (range 5-19 d) vs 
median 3.5 d (range 1-263 d), p = 0.02] and number 
of administrations [median 12 (range 8-18) vs median 
6 (range 1-22), p = 0.03] were significantly higher in 
those patients using gastro-protective drugs
Therapeutic management
Forty-eight (94%) of 51 patients underwent medical 
therapy [PPIs: 47 patients (98%); H2RAs: 1 patient 
(2%)] with spontaneous bleeding resolution. In 3 
patients (6%), an endoscopic hemostasis was needed 
(2 thermic and 1 mechanical). One (50%) of these 3 
patients experienced re-bleeding after 48 hours with 
the need of a second endoscopic examination. No case 
required surgical treatment.
DISCUSSION
To the best of our knowledge, this is the first Italian 
survey focusing on GI bleeding occurrences following 
NSAIDs consumption in a pediatric population. 
administrations per day [15/24 (62.5%)] and age of 
patients [4/24 (16.6%)]. In 31 (31.4%) of 51 patients, 
NSAIDs were taken without a medical prescription 
(Table 3).
Clinical features 
Hematemesis was the most frequent symptom, 
being present in 17 of 51 patients (33.3%). Age of 
children presenting with hematemesis was lower when 
compared to those with other symptoms, with a trend 
towards statistical significance [median age 6.1 years, 
range 5 mo-15 years vs median age 8 years, range 
1.4-15.2 years; p = 0.08)]. Sixteen out of 51 patients 
(31.3%) reported abdominal pain and heartburn, while 
melena was the main symptom in 4 of 51 patients 
(7.8%). Anemia was the only sign in 13 patients (25%). 
One patient experienced nausea and vomiting (1.9%). 
Endoscopic findings
All patients included in this study underwent upper GI 
endoscopy to exclude the presence of mucosal lesions. 
In 2 of 51 (3.9%) patients, ileocolonoscopy was also 
performed. Thirty-one of 51 patients (61%) required 
an emergency procedure, while in 20 patients (39%), 
the procedure was performed electively. Upper GI 
endoscopy confirmed the presence of gastric lesions 
in 32 (62%) of 51 patients, duodenal lesions in 17 
(33%) and esophageal lesions in 8 (15%). Upper 
Table 2  Reports on non-steroidal anti-inflammatory drugs  n  (%)
NSAIDs Patients Age (mo) Male gender Dose (mg/kg) No. of 
administrations
Duration (d)
Ibuprofen 35 (68.6)  66 (5-183)   20 (57.1) 10 (8-50)    7 (1-18)     4 (1-263)      
Ketoprofen 5 (9.8)  125 (27-180) 4 (80) 2 (1-3)         4 (2-15)   5 (1-18)
Acetylsalicic ac. 4 (7.8) 143.5 (113-170) 3 (75)   60 (5-200) 2.5 (1-22) 14 (2-25)
Flurbiprofen 3 (5.9)  100 (73-116)   3 (100) 20 (3-25)           6 (4-9) 4 (3-4)
Ketoralac 1 (2) 142   1 (100)   3   1 1
Naproxen 1 (2)   76   1 (100) 25   5 2
Niflumic ac. 1 (2) 139   1 (100) 25 10 5
Nimesulide 1 (2) 166   1 (100)   2   2 6
Continuous variables are expressed as median and range. ac: Acid; NSAIDs: Non-steroidal anti-inflammatory drugs.
Table 3  Appropriateness of use and medical prescription of 
non-steroidal anti-inflammatory drugs  n  (%)
NSAIDs (n) Inappropriate use1 Medical 
prescriptionWeight­dose  No. of 
administrations/d
Age 
Ibuprofen (35)    4 (11.4)  10 (28.5) 0  26 (74.3)
Ketoprofen (5) 1 (20) 2 (40) 0 3 (60)
Acetylsalicic ac. (4) 0 0 4 (100) 1 (25)
Flurbiprofen (3)    2 (66.7)    2 (66.7) 0    2 (66.7)
Ketoralac (1) 0   1 (100) 0   1 (100)
Naproxen (1)   1 (100)  0 0   1 (100)
Niflumic ac. (1) 0 0 0   1 (100)
Nimesulide (1) 0 0 0 0
1Number of patients inappropriately using NSAIDs in terms of weight-
dose, number of administrations per day, and age. ac: Acid; NSAIDs: Non-
steroidal anti-inflammatory drugs.
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Recently, Bianciotto et al[16], on behalf of the Italian 
Multicenter Study Group for Drug and Vaccine Safety 
in Children, reported an increased risk of UGIB 
associated with use of drugs, including NSAIDs, oral 
steroids and antibiotics. These data are in agreement 
with a warning published in 2010 by the Italian Drug 
Agency (AIFA), which warned of a significant increase 
of adverse NSAID-related reactions in children[17]. This 
increase was mainly referred to the rise of ibuprofen 
prescriptions from 0.7 × 100.000 in 2005 to 1.7 × 
100.000 in 2010[17]. Our data confirm a progressive 
increase of reports during the study-period. NSAIDs 
are commonly used agents in pediatrics for their 
anti-inflammatory, anti-pyretic and analgesic effects. 
Above all, ibuprofen use has been accepted, due to 
its safety profile, and demonstrated by two different 
large-scale studies[18,19]. These papers by Lesko et 
al[18,19], comparing the safety of acetaminophen 
and ibuprofen in children, showed no statistical dif-
ferences in gastrointestinal complications, even if 
hospitalizations for GI bleeding occurred only in those 
patients receiving ibuprofen. Indeed, Bianciotto et al[16] 
reported an adjusted OR of 3.8 for ibuprofen-related 
GI bleeding, while Grimaldi-Bensouda et al[13] reported 
an OR of 10. Not surprisingly, ibuprofen was the most 
used drug among our patients, being associated with 
GI bleeding in 68.6% of cases. In addition, ibuprofen 
use was significantly frequent in younger patients, 
confirming the safety perception of prescribing doctors 
and families[16]. On the contrary, the number of reports 
concerning the use of acetylsalicylic acid, aspirin, 
is rather alarming. In all of these cases, aspirin use 
should be considered inappropriate, since aspirin is 
indicated exclusively in patients older than 16 years. 
These data are similar to those reported by Grimaldi-
Bensouda et al[13] with striking difference that aspirin is 
not contraindicated in children in France. Nevertheless, 
the most alarming findings are those concerning 
NSAIDs prescription. Analysis of the appropriateness 
of drug consumption revealed that 47% of enrolled 
patients experienced an inappropriate use of medi-
cations in terms of weight-appropriate dose, number of 
administrations per day and patient age. Furthermore, 
in 31.4% of the cases, NSAIDs were taken without 
any medical prescription. These findings reinforce the 
hypothesis that at least in a subset of patients, NSAIDs 
GI toxicity is related to improper use rather than the 
safety profile of the molecules. 
The main indications for NSAID use was pain and 
fever, confirming the increasing tendency to prescribe 
NSAIDs, and mainly ibuprofen, for their antipyretic 
properties. It is generally assumed that gastrointestinal 
bleeding is associated with long-term use of NSAIDs[1]. 
However, in our study, the median time between 
NSAIDs use and GI bleeding was 4 d, highlighting 
that the adverse event may occur even during short-
term therapy. Hematemesis was the most frequent 
symptom, being present in 33.3% of the patients 
included in the study. In addition, this manifestation 
seems age-related, being significantly more frequent 
among younger children. This data could in someway 
be linked to the location of the lesions. Indeed, children 
of the youngest age group (≤ 3 years), showed more 
proximal lesions (esophagus and stomach) compared 
with the oldest age group (mainly duodenal lesions). 
Grimaldi-Bensouda et al[13] reported similar data, with 
esophageal lesions being more frequent in younger 
children. 
Table 4  Detailed endoscopic findings in 51 patients presenting 
with gastrointestinal bleeding after non­steroidal anti­
inflammatory drug use  n (%)
Variables ≤ 3 yr
(n  = 11)
> 3 ≤ 7 yr
(n  = 14)
> 7 ≤ 16 yr
(n  = 26)
P  value
Upper GI lesions 0.04
   Proximal (esophagus 
   and stomach)
10 (100)  12 (85.7) 15 (62.5)
   Distal (duodenum) 0    2 (14.3)   9 (37.5)
Location 0.06
   Esophagus    2 (18.1)    2 (14.3)   4 (15.4) 
   Stomach    8 (72.7)  10 (71.4) 11 (42.3)
   Duodenum 0    2 (14.3)   9 (34.6)
   Colon 1 (9) 0 1 (3.8)
Esophagus 0.90
   Upper 0 0 0
   Middle 0 0 0
   Lower    2 (18.1)    2 (14.3)   4 (15.3)
Los Angeles 
classification
0.50
   Grade A   2 (100)   2 (100) 3 (75)
   Grade B 0 0 1 (25)
   Grade C 0 0 0
   Grade D 0 0 0
Stomach 0.09
   Antrum 0 0   4 (36.4)
   Body 4 (50) 4 (40)   3 (27.3)
   Fundus 4 (50) 6 (60)   4 (36.4)
Type of lesions 0.40
   Erythema    5 (62.5) 8 (80)   4 (36.4)
   Edema 0 1 (10) 1 (9.1)
   Erosions 2 (25) 1 (10)   3 (27.3)
   Ulcerations    1 (12.5) 0   3 (27.3)
Duodenum 1.00
   Bulb 0   2 (100)   8 (88.9)
   Duodenum 0 0   1 (11.1)
Type of lesions 0.02
   Nodularity 0 1 (50)   1 (11.1)
   Erythema 0 1 (50) 0
   Erosions 0 0 0
   Ulcerations 0 0   8 (88.8)
Forrest Classification 
for ulcerations
0.30
   Grade 1a 0 0   2 (18.2)
   Grade 1b 0 0 1 (9.1)
   Grade 2a 1 (100) 0   2 (18.2)
   Grade 2b 0 0 0
   Grade 2c 0 0   2 (15.4)
   Grade 3 0 0   6 (54.5)
Colon
   Transverse 1 (9) 0 0
   Sigmoid 0 0 1 (3.8)
Type of lesions
   Erythema 1 (100) 0 0
   Edema 0 0  1 (100)
GI: Gastrointestinal; NSAIDs: Non-steroidal anti-inflammatory drugs.
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Although data in pediatrics are still limited, ac-
cording to the American College of Gastroenterology, 
the main risk factors for NSAID-related GI toxicity 
should be considered: the concomitant use of other 
medications (including corticosteroids, anticoagulants, 
antiplatelet), a history of previous peptic ulcer, H. pylori 
infection, prolonged or high-dose therapy[1]. In relation 
to these factors, certain groups of patients at greater 
risk may be identified and an adequate preventive 
strategy may be used[1]. Risk stratification does not 
seem to be translated in pediatric patients. Indeed, 
a high number of our patients showed significant 
risk factors for bleeding, including comorbidities, 
family history for peptic disease and active H. pylori 
infection. Concerning the association with H. pylori 
infection, it is still unclear whether NSAIDs GI toxicity 
is increased in patients with H. pylori gastritis[20]. Some 
authors suggest H. pylori detection and eradication 
at least in chronic users[21]. Another main risk factor 
is the use of other concomitant drugs. In our study 
population, 29.6% of patients had taken other drugs 
at the same time, including steroids, antibiotics 
and acetaminophen. In particular, concerning the 
concomitant use of ibuprofen and acetaminophen, the 
American Academy of Pediatrics strongly discourages 
the therapeutic association, due to the low benefit/
risk ratio[22]. The most common prevention strategies 
consist of the use of gastro-protective drugs. In 
our study population, 9.8% of enrolled patients 
used gastro-protective agents, and their use was 
significantly associated with duration of therapy and 
number of administrations, suggesting that prevention 
strategy is currently adopted only for longer courses of 
treatment. 
This study has several limitations. Besides the 
retrospective nature and therefore the possibility of 
recall biases, our study was mainly descriptive, since 
we did not have any comparison groups to draw 
definitive conclusions regarding overall NSAIDs safety. 
This survey represents the first Italian retrospective 
study on pediatric population to describe GI bleeding 
secondary to the use of NSAIDs. These data show 
that the risk of adverse events seems to be related 
to their improper use rather than to NSAIDs safety 
profile. The high number of self-prescriptions and 
the high percentage of inappropriate use represent 
the most alarming data. These findings underline the 
need for better promotion of NSAIDs use in children 
among general pediatricians and families, in order 
to prevent the occurrence of serious adverse events. 
Further studies are needed to better define possible 
risk stratification and preventive strategies in pediatric 
patients. 
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